{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"populationDescription":"All Treated Population. Participants with incomplete response dates were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Time to Response-Part 2","type":"SECONDARY"}